Anti-TCRβ mAb induces long-term allograft survival by reducing antigen-reactive T cells and sparing regulatory T cells

American Journal of Transplantation

Volumn 12, Issue 6, 2012, Pages 1409-1418

  Miyahara, Y ^a   Khattar, M ^a   Schroder, P M ^a   Mierzejewska, B ^a   Deng, R ^a,b   Han, R ^c   Hancock, W W ^c   Chen, W ^a   Stepkowski, S M ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Allograft survival; T cell receptor; T regulatory cells; tolerance

Indexed keywords

H 57 597; IMMUNOMODULATING AGENT; MONOCLONAL ANTIBODY; STAPHYLOCOCCUS ENTEROTOXIN B; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; CELL EXPANSION; CELLULAR IMMUNITY; CONTROLLED STUDY; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HOMEOSTASIS; IMMUNITY; IN VIVO STUDY; LYMPHOCYTE COUNT; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SINGLE DRUG DOSE; SKIN ALLOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; GRAFT SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MICE, INBRED STRAINS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION IMMUNOLOGY;

EID: 84862832381     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04006.x     Document Type: Review

References (34)

1. Rudolph MG, Stanfield RL, Wilson IA,. How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol 2006; 24: 419-466.
2. Teixeiro E, Daniels MA, Hamilton SE, et al,. Different T cell receptor signals determine CD8 +memory versus effector development. Science 2009; 323: 502-505.
3. Huppa JB, Axmann M, Mortelmaier MA, et al,. TCR-peptide-MHC interactions in situ show accelerated kinetics and increased affinity. Nature 2010; 463: 963-967.
4. Zehn D, Lee SY, Bevan MJ,. Complete but curtailed T-cell response to very low-affinity antigen. Nature 2009; 458: 211-214.
5. Sadelain M, Brentjens R, Riviere I,. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 2009; 21: 215-223.
6. Bielekova B, Martin R,. Antigen-specific immunomodulation via altered peptide ligands. J Mol Med 2001; 79: 552-565.
7. Valenta R, Ferreira F, Focke-Tejkl M, et al,. From allergen genes to allergy vaccines. Annu Rev Immunol 2010; 28: 211-241.
8. Chan AC, Carter PJ,. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010; 10: 301-316.
9. Kjer-Nielsen L, Dunstone MA, Kostenko L, et al,. Crystal structure of the human T cell receptor CD3 epsilon gamma heterodimer complexed to the therapeutic mAb OKT3. Proc Natl Acad Sci U S A 2004; 101: 7675-7680.
10. Salmeron A, Sanchez-Madrid F, Ursa MA, Fresno M, Alarcon B,. A conformational epitope expressed upon association of CD3-epsilon with either CD3-delta or CD3-gamma is the main target for recognition by anti-CD3 monoclonal antibodies. J Immunol 1991; 147: 3047-3052.
11. Gaston RS, Deierhoi MH, Patterson T, et al,. OKT3 first-dose reaction: Association with T cell subsets and cytokine release. Kidney Int 1991; 39: 141-148.
12. Chatenoud L, Bluestone JA,. CD3-specific antibodies: A portal to the treatment of autoimmunity. Nat Rev Immunol 2007; 7: 622-632.
13. You S, Chatenoud L,. New generation CD3 monoclonal antibodies: Are we ready to have them back in clinical transplantation? Curr Opin Organ Transplant 2010; 15: 720-724.
14. Sherry N, Hagopian W, Ludvigsson J, et al. Teplizumab for treatment of type 1 diabetes (Protege study): 1-Year results from a randomised, placebo-controlled trial. Lancet 2011; 378: 487-97.
15. Knight RJ, Kurrle R, McClain J, et al,. Clinical evaluation of induction immunosuppression with a murine IgG2b monoclonal antibody (BMA 031) directed toward the human alpha/beta-T cell receptor. Transplantation 1994; 57: 1581-1588.
16. Waid TH, Thompson JS, Siemionow M, Brown SA,. T10B9 monoclonal antibody: A short-acting nonstimulating monoclonal antibody that spares gammadelta T-cells and treats and prevents cellular rejection. Drug Des Devel Ther 2009; 3: 205-212.
17. Waid TH, Thompson JS, McKeown JW, Brown SA, Sekela ME,. Induction immunotherapy in heart transplantation with T10B9.1A-31: A phase I study. J Heart Lung Transplant 1997; 16: 913-916.
18. Waid TH, Lucas BA, Thompson JS, et al,. Treatment of renal allograft rejection with T10B9. 1A31 or OKT3: final analysis of a phase II clinical trial. Transplantation 1997; 64: 274-281.
19. Henrickson M, Reid J, Bellet JS, Sawchuk SS, Hirsch R,. Comparison of in vivo efficacy and mechanism of action of antimurine monoclonal antibodies directed against TCR alpha beta (H57-597) and CD3 (145-2C11). Transplantation 1995; 60: 828-835.
20. Drobyski WR, Majewski D,. Treatment of donor mice with an alpha beta T-cell receptor monoclonal antibody induces prolonged T-cell nonresponsiveness and effectively prevents lethal graft-versus-host disease in murine recipients of major histocompatibility complex (MHC)-matched and MHC-mismatched donor marrow grafts. Blood 1996; 87: 5355-5369.
21. Knight RJ, Kurrle R, Stepkowski S, Serino F, Chou TC, Kahan BD,. Synergistic immunosuppressive actions of cyclosporine with a mouse anti-rat alpha/beta-T cell receptor monoclonal antibody. Transplantation 1994; 57: 1544-1548.
22. Cai J, Terasaki PI,. Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data. Transplantation 2010; 90: 1511-1515.
23. Corry RJ, Winn HJ, Russell PS,. Primarily vascularized allografts of hearts in mice. The role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation 1973; 16: 343-350.
24. Ferraresso M, Tian L, Ghobrial R, Stepkowski SM, Kahan BD,. Rapamycin inhibits production of cytotoxic but not noncytotoxic antibodies and preferentially activates T helper 2 cells that mediate long-term survival of heart allografts in rats. J Immunol 1994; 153: 3307-3318.
25. Garrod KR, Cahalan MD,. Murine skin transplantation. J Vis Exp 2008; 634.
26. Strasser A, Harris AW, Vaux DL, et al,. Abnormalities of the immune system induced by dysregulated bcl-2 expression in transgenic mice. Curr Top Microbiol Immunol 1990; 166: 175-181.
27. Wu Z, Bensinger SJ, Zhang J, et al,. Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med 2004; 10: 87-92.
28. Lo DJ, Weaver TA, Stempora L, et al,. Selective targeting of human alloresponsive CD8+ effector memory T cells based on CD2 expression. Am J Transplant 2011; 11: 22-33.
29. Wang G, Miyahara Y, Guo Z, Khattar M, Stepkowski SM, Chen W,. "Default" generation of neonatal regulatory T cells. J Immunol 2010; 185: 71-78.
30. Wang G, Khattar M, Guo Z, et al,. IL-2-deprivation and TGF-beta are two non-redundant suppressor mechanisms of CD4+CD25+ regulatory T cell which jointly restrain CD4+CD25- cell activation. Immunol Lett 2010; 132: 61-68.
31. Guo Z, Wang G, Miyahara Y, et al,. IL-7, but not thymic stromal lymphopoietin (TSLP), during priming enhances the generation of memory CD4+ T cells. Immunol Lett 2010; 128: 116-123.
32. Belghith M, Bluestone JA, Barriot S, Megret J, Bach JF, Chatenoud L,. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 2003; 9: 1202-1208.
33. Lavasani S, Dzhambazov B, Andersson M,. Monoclonal antibody against T-cell receptor alphabeta induces self-tolerance in chronic experimental autoimmune encephalomyelitis. Scand J Immunol 2007; 65: 39-47.
34. Moder KG, Luthra HS, Kubo R, Griffiths M, David CS,. Prevention of collagen induced arthritis in mice by treatment with an antibody directed against the T cell receptor alpha beta framework. Autoimmunity 1992; 11: 219-224.